1. 171 Preclinical studies support therapeutic application of the leukemic cell-based cancer relapse vaccine DCP-001 in ovarian cancer. (10th December 2020) Authors: Nagasawa, Maho; Bos, Remco; Zuo, Haoxiao; Wang Yin, Kiave Yune Ho; Lierop, Marie-José van; Tabruyn, Sebastien; Manting, Erik; Bruyn, Marco de; Nijman, Hans; Singh, Satwinder KAur; Singh, Satwinder Kaur Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A102 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 171 Preclinical studies support therapeutic application of the leukemic cell-based cancer relapse vaccine DCP-001 in ovarian cancer. (9th November 2020) Authors: Nagasawa, Maho; Bos, Remco; Zuo, Haoxiao; Wang Yin, Kiave Yune Ho; Lierop, Marie-José van; Tabruyn, Sebastien; Manting, Erik; Bruyn, Marco de; Nijman, Hans; Singh, Satwinder KAur; Singh, Satwinder Kaur Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A185 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 2022-RA-1137-ESGO Use of an allogeneic, cell-based vaccine DCP-001 in high grade Serous Ovarian cancerpatients after primary treatment; A phase I clinical trial. (20th October 2022) Authors: Vledder, Annegé; van Zeeburg, Hester; Pas, Rob ten; Eerkens, Anje; Brummel, Koen; Wang Yin, Kiave Ho; Tabruyn, Sebastien; Singh, Satwinder Kaur; de Bruyn, Marco; Rovers, Jeroen; Nijman, Hans Wilhelm Journal: International journal of gynecological cancer Issue: Volume 32(2022)Supplement 2 Page Start: A304 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗